
News|Articles|September 10, 2024
Ethical, Biosafety, and Scientific Review Considerations in Hematology and Oncology Clinical Trials
Author(s)WCG Clinical
The current oncology and hematology drug development pipeline features a wide array of large molecule therapeutics. As a result, clinical trial protocols have grown more complex, requiring sponsors, CROs, and research sites to tackle a variety of challenges that were less common with older, more traditional therapies.
Trending on Applied Clinical Trials Online
1
FDA Finalizes Three Guidances to Broaden Cancer Clinical Trial Eligibility
2
Beyond Compliance: YPrime's Paulo Limgenco on Moving ESG From Reporting to Real Business Value
3
ACT Brief: Data Pipeline Standardization for Real-Time Analysis, Sponsor Accountability Beyond Contracts, and Autoimmune Pipeline Expansion
4
ACT Brief: Inspection Readiness Throughout Lifecycle, AI Churn and Operational Discipline, and Global Trial Stakeholder Alignment
5